FUNDAMENTALS · Fundamentals · KR Healthcare

GC (005250) Fundamentals 2026 — Revenue Analysis | SniperIQ

GC (005250) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩414.7B, trading at ₩9220.00 on the KSC. This SniperIQ fundamentals page covers GC's valuation, profitability (net margin -3.6%), revenue (₩2.45T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap₩414.7B
Net Margin-3.6%
Revenue (FY25)₩2.45T

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is GC's market cap?

GC (005250) has a market capitalization of approximately ₩414.7B, trading at ₩9220.00 on the KSC. Market cap moves with the live share price.

What is GC's P/E ratio?

GC's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is GC?

GC runs a net profit margin of -3.6%, a gross margin of 26.9%, and an operating margin of 1.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does GC generate?

GC reported revenue of ₩2.45T for fiscal year 2025, with net income of -₩69.5B and earnings per share (EPS) of -1531.06. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does GC pay a dividend?

GC offers a trailing dividend yield of about 3.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is GC financially healthy?

GC carries a debt-to-equity ratio of 1.88x and a current ratio of 0.94x, with a market beta of 0.56. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is GC a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For GC (005250) the key facts are: market cap ₩414.7B, revenue ₩2.45T, 52-week range 9060-18010. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track GC's full fundamentals live

Get GC's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Alfresa Holdings (2784) fundamentals · Aster DM Healthcare (ASTERDM) fundamentals · Ildong Pharmaceutical (249420) fundamentals · T&L (340570) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons